Data from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC
Julia Foldi(University of Pittsburgh), Lajos Pusztai(Yale University), Kerin B. Adelson(The University of Texas MD Anderson Cancer Center), David L. Rimm(Yale University), Andrea Silber, Emily Reisenbichler(Saint Louis University), Tristen Park, Kim Blenman(Medical University of South Carolina), Adriana Kahn, Justin Persico, Anamika Katoch, Qing Tao(Xinjiang University), Adam Blanchard, Neal Fischbach, Anees B. Chagpar(Yale University)
Cited by 0
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k